Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021)

Capricor Therapeutics' (CAPR) quarterly Notes Payables came in at $282691.0 in Q1 2021, up 14.59% quarter-over-quarter from $246689.0 in Q4 2020.

Capricor Therapeutics (CAPR) Notes Payables (2013 - 2021) Analysis & Trends

Capricor Therapeutics' Notes Payables history runs 3 years deep, the most recent figure standing at $282691.0 for Q1 2021.

On a quarterly basis, Notes Payables changed N/A year-over-year to $282691.0 in Q1 2021; TTM through Mar 2021 was $282691.0, a N/A change from a year earlier, with the FY2020 full-year figure at $246689.0, changed N/A from the prior year.
Notes Payables rose to $282691.0 in Q1 2021 per CAPR's latest filing, from $246689.0 in the prior quarter.
Across five years, Notes Payables topped out at $282691.0 in Q1 2021 and bottomed at $139927.0 in Q2 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	Capricor Therapeutics	457.86 Mn	457.86 Mn	-

Download Data